

Cosentyx 300mg UnoReady Pen Image





All the benefits of Cosentyx 300mg in ONE UnoReady® Pen¹

Image

maintenance injection
every month for patients
on 300 mg dose^{1*}

100% of patients were satisfied or very satisfied^{2†}

ALMOST ZERO injection site reactions (only 0.1 per 100 injections)^{2‡}

Cosentyx UnoReady pen self-injection video.

Cosentyx® (secukinumab) UnoReady® pen self-injection video



Patients can self-inject safely and confidently with a latex-free device

Patients can bear audio signals clearly when injection starts and is almost finished

No button to press¹

Designed for patients' comfort and convenience

Clear confirmation clicks¹

Patients can hear audio signals clearly when injection starts and is almost finished

Push-on-skin release for simple and ergonomic handling

- Rheumatology Prescribing CodesDermatology Prescribing Codes

Image

PBS Item Code	Indication	Treatment Phase	Max Qty	Repeats
14955D	Severe Psoriatic Arthritis	Initial Treatment – Initial 1,2,3	4	0
15018K	Severe Psoriatic Arthritis	Continuation	1	5
15027X	Severe Psoriatic Arthritis	Initial 1,2,3 balance of supply	1	2
14957F	Ankylosing Spondylitis	Initial Treatment – Initial 1,2,3	4	0
15029B	Ankylosing Spondylitis	Continuation	1	5
14956E	Ankylosing Spondylitis	Initial 1, 2, 3 insufficient treatment (balance of supply)	1	2
Image				

PBS Item Code	Indication	Treatment Phase	Max Qty	Repeats
15028Y	Severe Psoriasis	Initial Treatment – Initial 1,2,3	4	0
14972B	Severe Psoriasis	Continuation	1	5
14971Y	Severe Psoriasis	Initial 1,2,3 balance of supply	1	2
14154Y	Hidradenitis Suppurativa 150	Initial Treatment – Initial 1,2,3	4	0
14161H	Hidradenitis Suppurativa 150	Initial 1,2,3	1	3
15004Q	Hidradenitis Suppurativa 300	Initial Treatment – Initial 1,2,3	4	0
15030C	Hidradenitis Suppurativa 300	Initial 1,2,3	1	3
14970X	Hidradenitis Suppurativa 300	Continuation	1	5
14983N	Hidradenitis Suppurativa 300	Initial 1,2,3 balance of supply	1	3

Find out more about the Cosentyx patient support program





Patient Support Program


Article - 26 Mar 2025

Patient Support Program

<u>Facebook</u> <u>X</u> <u>Linkedin</u>



Hide details



urticaria, dermatitis (including eczema), rhinorrhoea, headache, nausea, hypercholesterolemia

References: 1. Cosentyx Approved Product Information. March 2025. **2.** Sigurgeirsson B et al. Dermatol Ther. 2022;35(3):e15285. doi:10.1111/dth.15285. doi:10.1111/jdv.12751.

Please refer to the full Cosentyx Prescribing Information here

Please refer to the full Cosentyx Consumer Medicine Information here

PBS Information: Section 85 Authority Required for the treatment of severe chronic plaque psoriasis, active ankylosing spondylitis, severe psoriatic arthritis, non-radiographic axial spondyloarthritis and hidradenitis suppurativa. Refer to PBS Schedule for full Authority information.

▼This medicinal product is subject to additional monitoring in Australia due to approval of an extension of indications. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Source URL: https://www.pro.novartis.com/au-en/cosentyx-300mg-unoready-pen